Inside the Verve Therapeutics offices (Kyle LaHucik for Endpoints News)
June 15, 2023 06:30 AM EDTUpdated 01:18 PM
Deals
Pharma
Cell/Gene Tx

Verve snags $60M from Lil­ly to tack­le Lp(a) with one-time gene edit­ing

Kyle LaHucik

Senior Reporter

Eli Lil­ly has tapped an­oth­er gene edit­ing part­ner, this time look­ing to go af­ter a large pa­tient pop­u­la­tion in the car­dio­vas­cu­lar space with the help …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Trump ad­min­is­tra­tion re­veals 'most fa­vored na­tion' drug price coun­try tar­gets

In his first ma­jor pol­i­cy roll­out, Vinay Prasad looks to chal­lenge ex­ist­ing 'dog­ma' on Covid vac­cines

Up­dat­ed: FDA ad­comm splits votes on Genen­tech and J&J can­cer drugs

RFK Jr. spars with sen­a­tors over re­search cuts, HHS bud­get plan

CRISPR Ther­a­peu­tics part­ners with siR­NA com­pa­ny, show­ing that gene edit­ing isn’t the on­ly an­swer

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times